# US 2021/0275682 A1 · Neoadjuvant use of antibody-drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275682 A1
- Document ID: US20210275682A1
- Status: Published application
- Kind: A1
- Application number: 17/171,411
- Filed: 2021-02-09
- Published: 2021-09-09
- Earliest claimed: 2009-02-13
- Assignees: Immunomedics, Inc.
- Applicants: Immunomedics, Inc.
- Inventors: David M. Goldenberg
- Web page: https://patentgrep.com/patent/US20210275682A1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6853: {Carcino-embryonic antigens}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

## Claims

### Claim 1

A method for neoadjuvant treatment of a cancer that expresses Trop-2 comprising:
a) administering an antibody-drug conjugate (ADC) to a subject with a cancer that expresses Trop-2, wherein the drug is SN-38 and the antibody is an anti-Trop-2 antibody comprising the light chain complementarity-determining region (CDR) sequences CDR1 (KASQDVSIAVA, SEQ ID NO:3); CDR2 (SASYRYT, SEQ ID NO:4); and CDR3 (QQHYITPLT, SEQ ID NO:5) and heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:6); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:7) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:8); and
b) treating the subject with surgery or radiation therapy, wherein the ADC is administered before the surgery or radiation therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody comprises human constant regions selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is a non-G1m1 (nG1m1) antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody has a G1m3 heavy chain allotype.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody has a nG1m1,2 heavy chain null allotype.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody has a Km3 light chain allotype.

### Claim 7 (depends on 1)

The method of claim 1, wherein the SN-38 forms intramolecular cross-links with the antibody or antigen-binding antibody fragment.

### Claim 8 (depends on 7)

The method of claim 7, wherein the intramolecular cross-links stabilize the conjugate in vivo and prevent release of free drug in circulation.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ADC comprises a linker that attaches the drug to the antibody.

### Claim 10 (depends on 9)

The method of claim 9, wherein the linker is CL2A.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering at least one therapeutic agent to said subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is refractory to other therapies but responds to therapy with neoadjuvant ADC.

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the neoadjuvant ADC.

### Claim 14 (depends on 1)

The method of claim 1, wherein treatment with the neoadjuvant ADC reduces the bulk of a primary tumor.

### Claim 15 (depends on 1)

The method of claim 1, wherein treatment with the neoadjuvant ADC reduces or eliminates one or more tumor metastases.
